Point72 Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $34.1M | Buy |
+1,130,507
| New | +$36.4M | 0.04% | 544 |
|
|
2024
Q4 | – | Sell |
-517,712
| Closed | -$9.42M | – | 2442 |
|
|
2024
Q3 | $9.33M | Sell |
517,712
-801,505
| -61% | -$14M | 0.02% | 667 |
|
|
2024
Q2 | $21.4M | Buy |
1,319,217
+363,217
| +38% | +$5.59M | 0.06% | 384 |
|
|
2024
Q1 | $13.5M | Sell |
956,000
-558,006
| -37% | -$7.03M | 0.03% | 606 |
|
|
2023
Q4 | $15.8M | Sell |
1,514,006
-117,191
| -7% | -$1.09M | 0.04% | 524 |
|
|
2023
Q3 | $16.6M | Buy |
1,631,197
+689,739
| +73% | +$6.42M | 0.05% | 459 |
|
|
2023
Q2 | $7.09M | Buy |
941,458
+941,399
| +1,595,592% | +$7.63M | 0.02% | 692 |
|
|
2023
Q1 | $522 | Buy |
+59
| New | +$583 | ﹤0.01% | 2139 |
|
|
2022
Q3 | – | Sell |
-6,653,979
| Closed | -$58.8M | – | 1728 |
|
|
2022
Q2 | $50M | Buy |
6,653,979
+5,424,079
| +441% | +$47.3M | 0.21% | 122 |
|
|
2022
Q1 | $11.5M | Buy |
+1,229,900
| New | +$10.3M | 0.05% | 470 |
|
|
2021
Q2 | – | Sell |
-1,568,700
| Closed | -$18.1M | – | 1162 |
|
|
2021
Q1 | $18.1M | Buy |
+1,568,700
| New | +$18M | 0.08% | 285 |
|
|
2020
Q4 | – | Sell |
-180,714
| Closed | -$1.63M | – | 1131 |
|
|
2020
Q3 | $1.63M | Buy |
+180,714
| New | +$1.91M | 0.01% | 726 |
|
|
2019
Q4 | – | Sell |
-27,409
| Closed | -$189K | – | 1241 |
|
|
2019
Q3 | $189K | Buy |
27,409
+14,519
| +113% | +$111K | ﹤0.01% | 918 |
|
|
2019
Q2 | $119K | Buy |
12,890
+9,698
| +304% | +$117K | ﹤0.01% | 1027 |
|
|
2019
Q1 | $50K | Buy |
+3,192
| New | +$56.3K | ﹤0.01% | 969 |
|
|
2018
Q4 | – | Sell |
-414,100
| Closed | -$8.92M | – | 1199 |
|
|
2018
Q3 | $8.92M | Sell |
414,100
-3,317,214
| -89% | -$77M | 0.04% | 484 |
|
|
2018
Q2 | $90.7M | Buy |
+3,731,314
| New | +$76.1M | 0.36% | 66 |
|
|
2018
Q1 | – | Sell |
-327,650
| Closed | -$6.21M | – | 1121 |
|
|
2017
Q4 | $6.21M | Buy |
327,650
+202,650
| +162% | +$3.05M | 0.03% | 549 |
|
|
2017
Q3 | $2.2M | Buy |
+125,000
| New | +$2.81M | 0.01% | 668 |
|
|
2016
Q1 | – | Sell |
-28,300
| Closed | -$1.86M | – | 844 |
|
|
2015
Q4 | $1.86M | Sell |
28,300
-345,500
| -92% | -$21.4M | 0.02% | 556 |
|
|
2015
Q3 | $21.1M | Buy |
373,800
+194,300
| +108% | +$12.6M | 0.17% | 185 |
|
|
2015
Q2 | $10.6M | Buy |
179,500
+88,500
| +97% | +$5.46M | 0.07% | 309 |
|
|
2015
Q1 | $5.67M | Sell |
91,000
-147,000
| -62% | -$8.55M | 0.04% | 420 |
|
|
2014
Q4 | $13.7M | Buy |
238,000
+178,800
| +302% | +$9.96M | 0.1% | 272 |
|
|
2014
Q3 | $3.18M | Sell |
59,200
-961,500
| -94% | -$50.9M | 0.02% | 456 |
|
|
2014
Q2 | $53.5M | Buy |
+1,020,700
| New | +$52.2M | 0.34% | 77 |
|
Other funds holding TEVA
HIIFS
PF
MMH
CI
MIFH
LIM
Point72 Asset Management's TEVA Position: Q1 2026 in Review
Point72 Asset Management opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 1,130,507 shares worth $34.1M. The stake represents 0.04% of the portfolio and ranks #544 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in TEVA as recently as Q3 2024.
Point72 Asset Management first reported a position in TEVA in Q2 2014 and has held it in 26 quarters since. The position peaked at $90.7M in Q2 2018. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.
- Point72 Asset Management held 1,130,507 shares of Teva Pharmaceuticals worth $34.1M as of Q1 2026.
- Teva Pharmaceuticals was a new Point72 Asset Management position in Q1 2026.
- Teva Pharmaceuticals made up 0.04% of Point72 Asset Management's portfolio in Q1 2026, its #544 holding.
- Point72 Asset Management first reported a position in Teva Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
- Point72 Asset Management's Teva Pharmaceuticals position peaked at $90.7M in Q2 2018.
- 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.